Angiotech anti-microbial catheters
This article was originally published in The Gray Sheet
Executive Summary
Vancouver firm initiates a 600-patient trial of drug-coated central venous catheter Jan. 5. The product, which will be submitted to FDA for 510(k)-clearance, is designed to prevent infections in critically ill patients with catheters inserted for extended periods. Angiotech describes the drug, 5-fluorouracil, as a "non-traditional anti-infective" because it is chemically different from currently used antibiotics, and, therefore, does not contribute to resistance to such drugs. Once enrollment is complete, the study, which will compare the product to an already approved anti-infective catheter, will take no more than 21 days, Anigotech says...
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.